Bristol-Myers Squibb (BMS) and Pfizer’s blood thinner Eliquis is poised to edge ahead of Johnson & Johnson’s Janssen Pharmaceuticals and Bayer’s Xarelto in 2017 and become the market leader. BMS CEO Giovanni Caforio added, “We think we are relatively close to achieving that.” Eliquis has already nabbed the top spot in the institutional setting, such as in hospitals and cardiologists’ offices, beating out long-used warfarin, and is making ground among primary care physicians. “We are beginning to see very, very strong momentum,” Caforio added. Xarelto and Eliquis were approved by the Food and Drug Administration (FDA) in 2011 and 2012, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.